Glenmark Pharmaceuticals · NSE: GLENMARK · BSE: 532296
Q4 FY24 results · Jan–Mar 2024
Glenmark Pharmaceuticals reported revenue from operations of ₹3,062.95 crore (down 9.2% from Q4 FY23) and net loss of ₹1,214.27 crore for Q4 FY24 (Jan–Mar 2024), on a consolidated basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,062.95 | 3,373.72 | −9.2% | 2,506.70 | +22.2% |
| Other income | 773.16 | (40.21) | Turned profit | 45.41 | 17x |
| Total income | 3,836.12 | 3,333.50 | +15.1% | 2,552.11 | +50.3% |
| Profit before tax | 530.83 | (490.77) | Turned profit | (521.38) | Turned profit |
| Net profit for the period | (1,214.27) | (403.14) | Loss widened | (330.82) | Loss widened |
| Attributable to shareholders of the company | (1,218.28) | — | — | (351.38) | Loss widened |
| EPS, basic (₹) | (43.18) | (15.18) | Loss widened | (12.45) | Loss widened |
| Net margin (%) | -39.6 | -11.9 | -13.2 |
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,148.22 | 1,939.05 | +10.8% | 1,365.10 | +57.4% |
| Other income | 786.27 | 232.97 | +237.5% | 258.81 | +203.8% |
| Total income | 2,934.49 | 2,172.01 | +35.1% | 1,623.91 | +80.7% |
| Profit before tax | 6,294.85 | (313.32) | Turned profit | (75.50) | Turned profit |
| Net profit for the period | 4,613.69 | (137.47) | Turned profit | (20.41) | Turned profit |
| EPS, basic (₹) | 163.50 | (4.87) | Turned profit | (0.72) | Turned profit |
| Net margin (%) | 214.8 | -7.1 | -1.5 |
Consolidated
- Filed with BSE
- 25 May 2024, 17:42 IST
- Board meeting
- 24 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 25 May 2024, 17:42 IST
- Board meeting
- 24 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE